Clinical Trials Browser

Terminated × INDUSTRY × Acrocephalosyndactylia × Clear all

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase 2 Terminated

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03144661 2025-10-21

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Phase 1 Terminated

GastrointestinalGynecologicHead & Neck

Acrocephalosyndactylia, Esophageal Neoplasms, Carcinoma, Hepatocellular, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma

NCT04604132 2024-04-04

FIDES-03

Phase 1/2 Terminated

47 enrolled 22 charts

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms